Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
1+PRN versus 3+PRN ranibizumab for macular edema secondary to branch retinal vein occlusion
ChiCTR2000038086Phase 4Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Oct 2018
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ranibizumab in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Best-corrected visual acuity at Week 48, Central retinal thickness at Week 48 and 1 more. Started Oct 2018; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ChiCTR2000038086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038086.